Roles
- Professor of Clinical Medicine
- Chief, Classical Hematology Section
-
Biography
Gerald Soff, M.D., is a Professor of Clinical Medicine in the Division of Hematology at the University of Miami Miller School of Medicine. He is a board-certified hematologist specializing in the management and study of non-neoplastic hematologic disorders, including thrombosis, blood coagulation, and disorders of red cells and platelets.
Dr. Soff earned his medical degree from The Johns Hopkins School of Medicine. He completed his residency training at the Medical College of Virginia and a hematology/oncology fellowship at Beth Israel Deaconess Medical Center and the Massachusetts Institute of Technology in Boston.
Throughout his career, Dr. Soff has held several leadership roles, including serving as Chief of the Division of Hematology/Oncology at SUNY Downstate Medical Center and as Chief of the Hematology Service at Memorial Sloan-Kettering Cancer Center (MSKCC). He currently serves as the Chief of the Classical Hematology Service at the University of Miami Health System/Sylvester Comprehensive Cancer Center. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 5 clinical trials.
-
To assess whether rosuvastatin 20 mg daily versus placebo over a period of one year reduces the risk of incident VTE (nonfatal lower or upper extremity DVT, nonfatal pulmonary embolism (PE), or death due to VTE) among patients recently diagnosed with cancer who are not scheduled to receive prophylactic anticoagulation and are at risk for VTE as defined by a Khorana Score (KS) of 2 to 4 or a modified Khorana Score (mKS) of 2 to 5. To assess whether rosuvastatin 20 mg daily vs placebo over a period of one year reduces the cumulative incidence of a composite of venous and arterial thrombosis (thus additionally including fatal and nonfatal myocardial infarction, thromboembolic stroke, and acute limb events) among patients recently diagnosed with cancer who are not scheduled to receive prophylactic anticoagulation and who are at risk for VTE as defined by a Khorana Score (KS) of 2 to 4 or a modified Khorana Score (mKS) of 2 to 5.
- Principal Investigator: Gerald Soff
- Study Phase: Phase IV
- Enrollment Status: Open
-
The main purpose of this trial is to do more research on how well the trial drug ianalumab is tolerated when given with background TPO-RA treatment (namely, avatrombopag, eltrombopag, or romiplostim) in people with primary ITP or primary Evans syndrome. Other purposes of the trial are to evaluate the safety and effectiveness of ianalumab in increasing platelet counts when used with background TPO-RA treatment, and to determine whether participants can be successfully tapered off their background TPO-RA treatment.
- Principal Investigator: Gerald Soff
- Study Phase: Phase II
- Enrollment Status: Open
-
The purpose of this study is to compare the effectiveness of the study drug Avatrombopag versus placebo (pills with no medicine) in treating persistent CIT in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. CIT is a common complication of cancer treatment that can cause chemotherapy delays, dose reductions, and treatment discontinuation.
- Principal Investigator: Gerald Soff
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer.
- Principal Investigator: Gerald Soff
- Study Phase: Phase III
- Enrollment Status: Closed
-
Evaluate the efficacy of REGN9933 and REGN7508 individually, eachcompared to placebo, for prevention of VTE after PICC placement. Assess the overall safety and tolerability of REGN9933 and REGN7508 individually.
- Principal Investigator: Gerald Soff
- Study Phase: Phase I/II
- Enrollment Status: Closed